RETEVMO

Eli Lilly and Company🇺🇸 United States

FDA Page

Effective Date: Sep 11, 2026
Approval ID: 7fa848ba-a59c-4144-9f52-64d090f4d828
Products: 6 registered
Version: 25

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO. RETEVMO (selpercatinib) capsules, for oral useRETEVMO (selpercatinib) tablets, for oral useInitial U.S. Approval: 2020

Quick Stats

Total Products6

Labelers2

Label Sections41

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.